Uniting Hearts and Pooling Strength to Innovate for a Bright Future — Aoxiang Pharmaceutical Grandly Holds the 2025 Annual Summary and Awards Ceremony and the 2026 Kickoff Meeting

Release Date:

2026-02-25

Uniting Hearts and Pooling Strength to Innovate for a Bright Future — Aoxiang Pharmaceutical Grandly Holds the 2025 Annual Summary and Awards Ceremony and the 2026 Kickoff Meeting

On the morning of February 24, 2026, Zhejiang Aoxiang Pharmaceutical Co., Ltd. held a grand ceremony to summarize and recognize achievements for the year 2025 and to mark the commencement of operations for 2026. With “Innovation Fuels the Future” as its central theme, the event aimed to reflect on the significant accomplishments of the past year, honor outstanding role models, and comprehensively launch a new journey of high-quality development in 2026.

Moment of Glory: Honoring Outstanding Contributions

The meeting was chaired by Zhang Huadong, Deputy General Manager of the company. To recognize the teams and individuals who made outstanding contributions over the past year, the chairperson read out on the spot the “Decision on Commending the Company’s Outstanding Teams and Individuals for 2025,” thereby expressing sincere respect to the teams and individuals who delivered exceptional performance in their respective roles throughout the past year.

Amid warm applause, the award recipients took to the stage one after another, where company leaders presented honorary awards to the outstanding employees and team representatives being recognized. Among them were seasoned technical experts who have dedicated themselves to frontline work, as well as pioneering market leaders who boldly explore new opportunities. Following the ceremony, the winners delivered remarks, sharing their personal journeys of hard work and dedication in their roles, along with invaluable insights and experiences, thereby showcasing the Ouxiang team’s spirit of striving for progress and pursuing excellence.

Strategic Leadership: Charting a New Blueprint for 2026

At the meeting, Chairman Zheng Zhiguo delivered a significant address titled “2025 Annual Summary and 2026 Work Report,” which comprehensively reviewed the company’s achievements in 2025, analyzed the current industry landscape, and outlined a detailed roadmap for achieving the strategic objectives for 2026.

In-depth Summary: Chairman Zheng Zhiguo provided a comprehensive review of the company’s breakthroughs in 2025 across key areas such as R&D innovation and capacity upgrades.
Situation Analysis: In the face of the rapidly evolving pharmaceutical industry landscape, the Chairman conducted an objective analysis, emphasizing the pivotal role of “innovation” in bolstering the company’s core competitiveness—provided that the fundamentals are firmly maintained and existing business operations are diligently managed.
Strategic Deployment: The report outlines the strategic priorities for 2026, calling on all employees to stay firmly aligned with the overarching theme of “Innovation Fuels the Future,” continuously drive the company’s sustained and stable development, and proactively pursue transformation and upgrading.

Responsibility and Commitment: Leading the Charge to Ensure Mission Success

To ensure that the annual objectives are fully realized, the meeting held a solemn ceremony for the signing of the 2026 Performance Agreements. Heads of all departments took to the stage to sign the agreements with great formality. These documents are not merely letters of commitment; they are also weighty statements of responsibility, signaling that the company has officially set out to accomplish all its 2026 tasks under unified leadership and demonstrating the unwavering resolve of the entire organization to fulfill its mission at all costs.

Moving Forward with Prudence: Solidifying the Bottom Line of Safe Production

Behind high-quality development lies rock-solid safety assurance. At the conclusion of the meeting, the company organized the “First Lesson of 2026: Safety Training” for the resumption of work. Chairman Zheng Zhiguo personally delivered the lecture, emphasizing ten key principles for ensuring effective implementation and execution upon resuming operations. He stated clearly: “The key to safety is prioritization; the key to prioritization is leadership; and the key to leadership is deep engagement.” This session served as a powerful reminder to all employees that, while striving for performance and profitability, they must firmly uphold the safety bottom line to ensure the stable and sustainable operation of the enterprise.

The clarion call for 2026 has already sounded. All members of Aoxiang will take this conference as an opportunity to unite closely and forge ahead with determination, advancing with even greater confidence and a more pragmatic approach toward our new goals, and together write a new, even more glorious chapter for Aoxiang Pharmaceutical!